Bisphosphonate-Associated Ocular Adverse Events with an Emphasis on Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Bisphosphonate use is associated with a significantly higher risk of developing ocular adverse events, including uveitis. The first three days following intravenous bisphosphonate administration are associated with an elevated risk of developing ocular adverse events.